13 projects have been signed with strong growth momentum in biomedical industry

The development of biomedicine will help to solve the problem of human genetic disease treatment, improve the average life span of the people, and have a profound impact on human health In recent years, China's pharmaceutical industry has developed rapidly It is expected that during the 13th Five Year Plan period, the biomedical industry will also maintain a rapid growth momentum The author has learned that, on February 28, the production and pharmaceutical industry flourished in Chengdu high tech Zone, Sichuan Province, with 13 projects signed and a total investment of more than 8.4 billion yuan, of which 12 projects with a total investment of about 7.4 billion yuan were signed and settled in Chengdu Tianfu international bio City, and the West China high tech bio pharmaceutical Valley project with a total investment of 1.02 billion yuan was signed and settled in Chengdu high tech Zone After these 13 projects are completed and put into operation, the annual revenue is expected to exceed 10 billion yuan The signed projects have a complete range of business forms, covering such industry segments as biomedicine, biomedical engineering, biological services and intelligent health The signed enterprises include the global top 500, listed enterprises on the new third board, listed enterprises, professional research institutions of traditional Chinese medicine, pre bed safety evaluation institutions in the top 20 in the world, drug research and development institutions, overseas returned high-level talent entrepreneurial groups Team, provincial level three class a maternal and child health institutions, world scale comprehensive single point hospital Strong squad The overall flowering of biomedical projects in Chengdu high tech Zone also indicates the increase of the development of biomedical in China The author has learned that the development of biomedical industry in China is in a good situation, but the whole industry is still in the early stage of development There are many, small and scattered problems in biomedical companies, which affect the normal development of biomedical industry To form a sound development of biomedical industry, it needs the joint efforts of government departments, R & D institutions and enterprises He Wei, Deputy Secretary General of the CPPCC National Committee and vice chairman of the Central Committee of the labor party, pointed out that the development of biomedicine should focus on the major needs of biomedical R & D and industrialization In the top-level design, first of all, we need to highlight the leading role of value rationality; second, we need to pay attention to the instrumental rationality of multi-element reorganization to realize the organic unity of talents, capital, technology and market; third, we need to explore the establishment of a new R & D organization with high R & D efficiency, and turn the traditional sequential and isolated R & D model into a new parallel and interactive innovative R & D model He Wei deeply analyzed the necessity of establishing the pharmaceutical exchange from six basic characteristics of the biomedical industry: first, strategic, second, strict supervision, third, high-tech, fourth, clear industrial division (monopoly), fifth, intellectual property protection, sixth, strong technology dependence He believes that it is necessary to set up a drug exchange from both the perspective of the configuration of the whole industrial chain of biomedicine and the perspective of R & D model He stressed that we should consider how to build this platform from the necessary attributes of the drug exchange: sex, professionalism, commerciality, openness and participation As one of the main industries, there are nearly 200 developing and provincial-level parks in China, which contribute more than 30% to the output value of the national biological industry The number of clustered biomedical enterprises accounts for about 32% of the national total, and the number of biomedical R & D personnel accounts for 40% of the national total A number of leading enterprises have been cultivated It has formed a number of specialized high-tech parks, as well as biomedical industry cluster areas with Yangtze River Delta, Bohai rim and Pearl River Delta as the core China's biopharmaceutical market space and industry scale are huge, and the biopharmaceutical industry is expected to become the next "investment outlet" According to the 13th five year plan for the development of biological industry, by 2020, the scale of biological industry will reach 8 trillion-10 trillion yuan, with the added value accounting for more than 4% of GDP, which is doubled compared with the scale of 3.5 trillion yuan in 2015; specifically for the pharmaceutical industry, it is required to achieve 4.5 trillion yuan of industrial sales revenue by 2020, with the added value accounting for 3.6% of the national industrial added value According to the plan, the annual compound growth rate of the scale of biological industry is about 20%, which is significantly higher than the average growth rate of the pharmaceutical industry Under the new normal that the overall growth rate of the pharmaceutical industry is slowing down, the biomedical industry in line with the direction of innovation will undoubtedly become the focus of development Driven by a series of industrial policies, domestic drug innovation and drug quality improvement will enter a golden age As a result of the policy, the biomedical industry should seize the opportunity, make continuous technological innovation, and promote the rapid and healthy development of the biomedical industry.